Widely read:
Adobe Stock
Summary: Laurus Labs trades at nearly 85x earnings even as its profits remain uneven. The market appears to be betting on a shift that can reshape the company’s growth and margin profile. Is this optimism justified? Find out below
At nearly 85 times earnings, Laurus Labs looks like a stock the market should be staying away from. Brokerages have been cautious while earnings have been volatile for some time. And traditional valuation metrics offer little comfort for the generic player. And yet, the share price is on a roll, up 23 per cent in the last three months.
What explains this performance is a business transformation that the market appears to be pricing well in advance. Laurus is no longer being seen only as an anti-retroviral (ARV) generics (used to treat HIV) player. Increasingly, it is being viewed as a science-led contract manufacturing or CDMO platform in the making.
The question that demands an answer now is simple: has the market got ahead of itself, or is this a case where the price is actually a reflection of coming growth? Let’s examine.
A transformation spanning a decade
Laurus’s evolution did not happen overnight. Over the past 10 years, the company has methodically moved up the value chain. In the early phase, between FY15 and FY18, Laurus built a strong franchise in ARV APIs and formulations. This gave it scale, cost leadership and execution credibility but also left it exposed to price pressure and concentration risk.
The next phase, from FY19 to FY21, saw the company expand beyond ARVs into non-ARV APIs and oncology formulations, while quietly investing in custom synthesis capabilities. These moves attracted limited attention at the time but laid the groundwork for a broader platform.
The real shift has followed from FY22 onwards when volatility in the ARV business exposed the limits of the old model. Management has responded by accelerating investments in CDMO, biologics, peptide chemistry and cell and gene therapy.
Between FY22 and FY26, Laurus has committed more than Rs 3,000 crore in capex, with nearly three-quarters directed towards API and CDMO expansion.
Key initiatives include:
- A large integrated campus in Vizag, spread over more than 500 acres, with planned investment of around $600 million over time.
- Early investments in fermentation, ADC and gene therapy platforms, built ahead of demand rather than in response to it.
How the shift to CDMO is showing up in numbers
Recent performance offers early evidence of this transition. Even as ARV sales have fluctuated, Laurus has delivered sequential revenue growth, thanks to the increasing contribution from the CDMO segment, which now accounts for over 30 per cent of revenues compared with roughly 10–15 per cent in earlier years.
CDMO is increasingly becoming the company’s core growth engine. And the economics here are more favourable than in commodity APIs. Higher-value CDMO projects tend to offer:
- Better margins than generics.
- Recurring revenues once commercial supplies begin.
- Longer customer relationships and improved visibility.
The industry backdrop is also positive
The optimism around Laurus is also shaped by broader industry trends. Global pharma companies are actively diversifying supply chains under China+1 and Europe+1 strategies. At the same time, demand is shifting towards more complex chemistries such as biologics, peptides, ADCs and GLP-1-related molecules.
Indian CDMO players that combine cost efficiency with regulatory credibility are well placed to benefit. Industry growth is projected at a healthy pace over the next few years and the number of companies that can offer scale, technology and execution reliability remains limited.
Laurus’ investment has helped it position itself in this space. It operates one of the largest reactor capacities in India and has built capabilities across high-potent APIs, flow chemistry, continuous manufacturing, biocatalysis, fermentation, peptides, ADC payload-linkers and cell and gene therapy platforms. Its rapid scale-up for Paxlovid production (Pfizer’s antiviral) has also strengthened its execution credentials with global customers.
All of this explains why the market is willing to look through near-term volatility. Investors are not paying 85x earnings for today’s profits, but for the possibility of regular cash flows from a scaled CDMO platform.
The margin inflection investors are watching
The most important change may ultimately show up in margins. CDMO carries structurally higher profitability than generics and as its share increases further, overall margins should improve. Operating leverage from newly built capacities could further support this shift.
Management has guided towards:
- Double-digit revenue growth in FY26 with a stronger second-half skew as CDMO projects scale.
- Gross margins of around 55–60 per cent supported by a richer CDMO mix.
- EBITDA margins sustained above 20 per cent as utilisation improves across new capacities.
If this holds true, Laurus’s earnings profile could look meaningfully stronger over the next 18–24 months.
What can go wrong
At the same time, this is not a risk-free story. At current valuations, execution matters enormously.
Key risks include:
- Execution risk in CDMO, where delays, quality issues or compliance lapses can quickly damage credibility.
- Revenue lumpiness, as individual projects can have an outsized impact on quarterly numbers.
- Continued volatility in the legacy ARV and formulations businesses.
- Rising competition within Indian CDMO, increasing the need for continuous differentiation.
- High valuation sensitivity, where even small disappointments can trigger sharp market reactions.
This is not a “growth at any cost” narrative. It is a high-expectation story with limited room for error.
What should investors watch for
The debate ultimately comes down to how investors view Laurus’ identity. Is it still a generics company enjoying a favourable CDMO phase or is it evolving into a long-duration, science-led outsourcing platform?
If the latter plays out, today’s valuation may eventually look reasonable in hindsight. If execution falters, the same valuation could feel unforgiving. The market has already placed its bet. The next few quarters will decide whether Laurus can turn expectation into delivery.
Where to find stocks that actually excel on execution
High-valuation turnarounds reward investors who spot execution early—and punish those who don’t track it closely. With Value Research Stock Advisor, you get clear, independent calls on whether such transformations are worth betting on, what milestones matter, and when optimism turns excessive. Subscribe to stay ahead of market narratives—and invest with conviction, not hope.
Also read: Can a bigger Devyani revive Pizza Hut?
This article was originally published on January 18, 2026.
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
